Advertisement
Screener

BIOVENTUS INC. (BVS) Overview

BIOVENTUS INC. (BVS) Overview

  • 29 Mar 2026: Period ending 27 Jun 2026; Estimate (m); Actual 0.47; Beat / miss (m).
  • 1 Jan 2026: Period ending 28 Mar 2026; Estimate (m); Actual 0.04; Beat / miss (m).
  • 29 Jun 2025: Period ending 27 Sept 2025; Estimate (m); Actual 0.05; Beat / miss (m).
  • 30 Mar 2025: Period ending 28 Jun 2025; Estimate (m); Actual 0.11; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$6.20$7.50$9.07$10.96$13.25$16.022025-11-062026-11-06$0.88$1.60$2.91$5.28$9.59$17.412021-11-082026-11-06$0.88$1.65$3.09$5.77$10.79$20.172021-02-112026-11-06$0.88$1.65$3.09$5.77$10.79$20.172021-02-112026-11-06$0.88$1.65$3.09$5.77$10.79$20.172021-02-112026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$10.60
Previous close
$14.00
Change
-$3.40
Change (%)
-24.29%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BVS
+88.17%
S&P 500
(m)

1 year

BVS
+111.48%
S&P 500
(m)

3 years

BVS
+324.24%
S&P 500
(m)

5 years

BVS
-2.91%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

27 Jun 2026 ○ Estimate (m) ● Actual 0.47

-0.120.070.260.460.6529 Mar 2025: estimate (m); actual -0.0429 Mar 2025(m)28 Jun 2025: estimate (m); actual 0.1128 Jun 2025(m)27 Sept 2025: estimate (m); actual 0.0527 Sept 2025(m)28 Mar 2026: estimate (m); actual 0.0428 Mar 2026(m)27 Jun 2026: estimate (m); actual 0.4727 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
29 Mar 202627 Jun 2026(m)0.47(m)(m)
1 Jan 202628 Mar 2026(m)0.04(m)(m)
29 Jun 202527 Sept 2025(m)0.05(m)(m)
30 Mar 202528 Jun 2025(m)0.11(m)(m)
1 Jan 202529 Mar 2025(m)-0.04(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.33

-2.67-1.88-1.08-0.290.5131 Dec 2021: estimate (m); actual -0.1531 Dec 2021(m)31 Dec 2022: estimate (m); actual -2.5931 Dec 2022(m)31 Dec 2023: estimate (m); actual -2.4931 Dec 2023(m)31 Dec 2024: estimate (m); actual -0.5631 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.3331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.33(m)(m)
1 Jan 202431 Dec 2024(m)-0.56(m)(m)
1 Jan 202331 Dec 2023(m)-2.49(m)(m)
1 Jan 202231 Dec 2022(m)-2.59(m)(m)
1 Jan 202131 Dec 2021(m)-0.15(m)(m)

Revenue vs. Earnings

USD

27 Jun 2026 ■ Revenue 153.21M ■ Earnings 33.44M — Profit margin 21.83%

-18.95M1.3%46.32M8.5%111.58M15.6%176.85M22.8%27 Sept 2025: revenue 138.65M; earnings 3.15M; profit margin 2.28%27 Sept 202531 Dec 2025: revenue 157.90M*; earnings 14.76M*; profit margin 9.34%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-09-28 to 2025-12-31; USD.31 Dec 202528 Mar 2026: revenue 132.09M; earnings 3.11M; profit margin 2.36%28 Mar 202627 Jun 2026: revenue 153.21M; earnings 33.44M; profit margin 21.83%27 Jun 2026

31 Dec 2025 ■ Revenue 568.09M ■ Earnings 22.73M — Profit margin 4.00%

-246.54M-32.0%56.01M-19.7%358.56M-7.3%661.12M5.0%31 Dec 2022: revenue 512.12M; earnings -158.70M; profit margin -30.99%31 Dec 202231 Dec 2023: revenue 512.35M; earnings -156.23M; profit margin -30.49%31 Dec 202331 Dec 2024: revenue 573.28M; earnings -36.13M; profit margin -6.30%31 Dec 202431 Dec 2025: revenue 568.09M; earnings 22.73M; profit margin 4.00%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$10.60(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$10.60High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning BVS

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 27 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$54.46M
Profit margin
9.36%
Return on assets · 12 month
7.89%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
930.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
499.56K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
2.56%*
Total return · month
1.16%*
Total return · quarter
43.15%*
Total return · half year
56.60%*
Total return · year to date
88.17%*
Total return · 1 year
111.48%*
Total return · 3 years
324.24%*
Total return · 5 years
-2.91%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$581.85M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
108.82%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

BIOVENTUS INC. Overview

View more →

(m)

(m)

SEC CIK
1665988
Industry (SIC)
3841 Surgical & Medical Instruments & Apparatus
Country of operation
United States
Business address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, North Carolina, 27703, United States
Fiscal year end
1231
Phone
(919) 474-6700